Targeting the IGF1 axis in cancer proliferation

被引:80
作者
Bruchim, Ilan [1 ,2 ]
Attias, Zohar [1 ]
Werner, Haim [1 ]
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel
[2] Meir Med Ctr, Gynecol Oncol Unit, Dept Obstet & Gynecol, IL-44281 Kefar Sava, Israel
基金
美国国家科学基金会;
关键词
IGF-1 receptor (IGF1R); insulin-like growth factors (IGF); monoclonal antibodies; targeted therapy; tyrosine kinase inhibitors; GROWTH-FACTOR-I; RECEPTOR GENE-EXPRESSION; EPITHELIAL OVARIAN-CANCER; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODY CP-751,871; PRIMARY PROSTATE-CANCER; BINDING PROTEIN-3; FACTOR (IGF)-I; INSULIN-LIKE-GROWTH-FACTOR-1; RECEPTOR; INSULIN-RECEPTOR;
D O I
10.1517/14728220903201702
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
The IGF network of ligands, cell-surface receptors and IGF-binding proteins has important roles at multiple levels, including the cellular, organ and organism levels. The IGF system mediates growth, differentiation and developmental processes, and is also involved in various metabolic activities. Dysregulation of IGF system expression and action is linked to diverse pathologies, ranging from growth deficits to cancer development. Targeting of the IGF axis emerged in recent years as a promising therapeutic approach in conditions in which the IGF system is involved. Specific IGF1 receptor (IGF1R) targeting, in particular, produced the best experimental and clinical results so far, and generated significant optimism in the field. This review provides a basic analysis of the role of the IGF1R in cancer biology and explores the functional interactions between the IGF signaling pathways and various cancer genes (e.g., oncogenes, tumor suppressors). In addition, we review a number of specific malignancies in which the IGF system is involved and summarize recent data on preclinical and clinical studies employing IGF1R-targeted modalities.
引用
收藏
页码:1179 / 1192
页数:14
相关论文
共 128 条
[1]
BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene [J].
Abramovitch, S ;
Glaser, T ;
Ouchi, T ;
Werner, H .
FEBS LETTERS, 2003, 541 (1-3) :149-154
[2]
THE INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR GENE IS THE TARGET FOR THE 15Q26 AMPLICON IN BREAST-CANCER [J].
ALMEIDA, A ;
MULERIS, M ;
DUTRILLAUX, B ;
MALFOY, B .
GENES CHROMOSOMES & CANCER, 1994, 11 (01) :63-65
[3]
Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas [J].
Andrews, DW ;
Resnicoff, M ;
Flanders, AE ;
Kenyon, L ;
Curtis, M ;
Merli, G ;
Baserga, R ;
Iliakis, G ;
Aiken, RD .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2189-2200
[4]
Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer [J].
Ayabe, T ;
Tsutsumi, O ;
Sakai, H ;
Yoshikawa, H ;
Yano, T ;
Kurimoto, F ;
Taketani, Y .
ENDOCRINE JOURNAL, 1997, 44 (03) :419-424
[5]
Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer [J].
Baglietto, Laura ;
English, Dallas R. ;
Hopper, John L. ;
Morris, Howard A. ;
Tilley, Wayne D. ;
Giles, Graham G. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2007, 16 (04) :763-768
[6]
The somatotropic axis and aging: Mechanisms and persistent questions about practical implications [J].
Bartke, Andrzej .
EXPERIMENTAL GERONTOLOGY, 2009, 44 (6-7) :372-374
[8]
The igf-1 receptor in cancer biology [J].
Baserga, R ;
Peruzzi, F ;
Reiss, K .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (06) :873-877
[9]
The contradictions of the insulin-like growth factor 1 receptor [J].
Baserga, R .
ONCOGENE, 2000, 19 (49) :5574-5581
[10]
Beech DJ, 2001, ONCOL REP, V8, P325